Showing 16,881 - 16,900 results of 43,028 for search '(( 5 ((mean decrease) OR (point decrease)) ) OR ( 100 ((we decrease) OR (a decrease)) ))', query time: 1.38s Refine Results
  1. 16881

    Qatar University culture collection: A source of biodiversity and numerous applications by Al Ghazal, Ghamza

    Published 2016
    “…During their phases of growth, they produce a variety of metabolites such as lipids, proteins and carbohydrates in large amounts over a short period of time. …”
    Get full text
    Get full text
  2. 16882
  3. 16883

    Association between post-transplant serum uric acid levels and kidney transplantation outcomes by Deok Gie Kim (6086909)

    Published 2018
    “…Patients (n = 2,993) were divided into low-, normal-, and high-UA groups according to the mean serum UA level within the first year (1-YR) and 1–5 years (5-YR) after transplantation.…”
  4. 16884

    mRNA expression of HO-1 (A), CXCL10 (B), and CXCR3 (C) in whole brain homogenates of control, ARM, ATV, ATV/ARM-treated<i> P. berghei</i>ANKA-infected mice (  = 5 per group). by Nana O. Wilson (399957)

    Published 2013
    “…<p>Expression, measured by real-time PCR on day 11 post infection, is relative to the mean expression value in untreated mice day 5 post-infection brain samples and normalized on HPRT values. …”
  5. 16885
  6. 16886

    Wind Reversals During Morning and Evening Transitions in a Small Valley by Rui Zhang (20177106)

    Published 2025
    “…The outmost domain covers an area of 500×500 km with a horizontal grid spacing of 3 km. The horizontal grid spacing decreases to 1 km for d02 and 0.33 km for d03, while d02 and d03 cover an area of 100×100 km and 10×10 km, respectively. …”
  7. 16887

    GJIC has a dual effect on Cd-induced cytotoxic injury. by Hui Zou (666389)

    Published 2015
    “…<p><b>a</b>: Effect of Sal on the Cd-induced down-regulation of GJIC in BRL 3A cells and rat liver tissue(Cd 2.5 means 2.5μm Cd, Cd 10 means 10μm Cd). …”
  8. 16888

    The LDL-HDL Profile Determines the Risk of Atherosclerosis: A Mathematical Model by Wenrui Hao (534305)

    Published 2014
    “…Simulations of the model show how the combination of the concentrations of LDL and HDL in the blood determine whether a plaque will grow or disappear. More precisely, we create a map, showing the risk of plaque development for any pair of values (LDL,HDL).…”
  9. 16889

    Overdiagnosis and overtreatment of thyroid cancer: A population-based temporal trend study by Sabrina Jegerlehner (4110049)

    Published 2017
    “…</p><p>Results</p><p>Between 1998 and 2012, the age-standardized annual incidence of thyroid cancer increased from 5.9 to 11.7 cases/100,000 among women (annual mean absolute increase: +0.43/100,000/year) and from 2.7 to 3.9 cases/100,000 among men (+0.11/100,000/year). …”
  10. 16890

    Phenotypic and genotypic analysis following treatment of incrossed heterozygous <i>bmp4</i><sup><i>st72/+</i></sup> zebrafish with 0 μM, 0.25 μM and 0.5 μM PTC124. by Max Krall (6631025)

    Published 2019
    “…The probability of tail fin defect decreased from 81.08% to 74.07% and 37.50% as the dose increased to 0.25 μM and 0.5 μM. …”
  11. 16891
  12. 16892
  13. 16893

    2-DOG blocks Aβ-induced neuronal ROS formation. by Leonardo M. Saraiva (358796)

    Published 2013
    “…Scale bar corresponds to 100 µm. Panel E: 2-DOG decreases neuronal G6P levels in neurons exposed to Aβ. …”
  14. 16894
  15. 16895
  16. 16896
  17. 16897
  18. 16898
  19. 16899

    Data_Sheet_1_Modeling the Bioaccumulation and Biomagnification Potential of Microplastics in a Cetacean Foodweb of the Northeastern Pacific: A Prospective Tool to Assess the Risk E... by Juan José Alava (8601561)

    Published 2020
    “…To understand whether microplastics bioaccumulate in marine mammals, a bioaccumulation model for MPs was developed for the filter-feeding humpback whale and fish-eating resident killer whale foodwebs of the Northeastern Pacific. …”
  20. 16900

    Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials by Tao Cheng (1235148)

    Published 2016
    “…The onabotulinumtoxinA-treated groups had a significantly decreased mean number of urinary incontinence episodes per week (at week 6) (onabotulinumtoxinA200U: MD: -10.72, 95% CI: -13.4 to -8.04, P<0.00001; 300 U: MD: -11.42, 95% CI: -13.91 to -8.93, P<0.00001), MDP (200 U: MD: -33.46, 95% CI: -39.74 to -27.18, P<0.00001; 300 U: MD: -31.72, 95% CI: -37.69 to -25.75, P<0.00001), and greater increased MCC (200 U: MD: 141.30, 95% CI: 121.28 to 161.32, P<0.00001; 300 U: MD: 151.39, 95% CI: 130.43 to 172.34, P<0.00001) compared to the placebo-treated groups. …”